Talphera Files Prospectus for Resale of Up to 30.88M Shares by Selling Stockholders

Talphera has filed a prospectus for the resale of up to 30.88M shares of common stock, including 25.04M shares and 5.85M shares issuable upon exercise of pre-funded warrants, acquired by selling stockholders under a securities purchase agreement.

Talphera (NASDAQ: TLPH) has filed a prospectus with the Securities and Exchange Commission (SEC) for the resale of up to 30.88 million shares of its common stock. This includes 25.04 million shares and 5.85 million shares issuable upon the exercise of pre-funded warrants. The shares were acquired by selling stockholders under securities purchase agreements dated September 7, 2025. Notably, Talphera is not selling any shares itself and will not receive proceeds from the resale by stockholders Talphera files prospectus for resale of up to 30.9M shares by selling stockholders^[1].

This move comes amidst the company's recent earnings call where Talphera announced a private placement financing of up to $29 million, priced at the market, and outlined an accelerated enrollment for its NEPHRO protocol along with a reduction in 2025 cash operating expense guidance due to a protocol shift .

The resale of shares is a common practice in the financial markets, allowing stockholders to liquidate their holdings without the company directly selling its shares. This prospectus filing is a procedural step to ensure the resale complies with SEC regulations.

Investors and financial professionals should monitor this development closely to understand its implications on Talphera's stock price and overall market position. Further details and updates will be available in the SEC filing and through Talphera's official channels.